ACS CAN advocates for policies that provide access to treatments and services people with cancer need for their care - including those who may be newly diagnosed, in active treatment and cancer survivors.
Eye on Cancer Care is a series of white papers and one-pagers that spotlight key access-to-care issues central to ACS CAN’s mission to fight cancer. Ensuring that everyone has access to comprehensive, affordable health coverage and care is essential.
Access to lifesaving preventive services, including cancer screening, relies on federal preventive care recommendations and guidelines that determine which screenings, tests, and services health insurance plans must cover without cost sharing, including who is eligible, the age at which services
ACS CAN’s Vaccination Policies and the Impact on the Cancer Community: The Important Role of Childhood Immunization report outlines the critical importance of childhood immunizations for people with cancer and their families, and why maintaining high vaccination coverage among ch
The American Cancer Society (ACS) and the American Cancer Society Cancer Action Network (ACS CAN) are pleased to provide comments to the Advisory Committee on Immunization Practices (ACIP). Our comments reflect our commitment to cancer prevention and control and focus on ensuring that the Centers for Disease Control and Prevention’s (CDC) immunization schedules are grounded in strong scientific evidence, and provide clear, actionable information to healthcare professionals, parents, and payers.
Our latest Survivor Views survey underscores the critical role of evidence-based vaccinations in promoting public health and protecting communities impacted by cancer. Cancer patients and survivors overwhelmingly agree on the importance of community immunization, oppose limits to vaccine access, and support school entry requirements. In addition, the survey finds strong support for investment in the oncology potential of vaccines.
Our latest Survivor Views survey finds nearly three in four cancer patients and survivors who rely on the marketplace for comprehensive coverage stand to lose access to lifesaving care if the enhanced premium tax credits are not extended. Additionally, one quarter of those who rely on the enhanced health care tax credits report that if the credits expire, they will become uninsured or forced into a non-comprehensive "junk" plan.
Nearly all (94%) cancer patients and survivors agree that it is important for patients and their providers to have the ability to choose the type of treatment and delivery that best suits their needs. Patients who have taken oral anti-cancer drugs rate their experience significantly better compared to experiences with IV infusions on several metrics including coping with side effects, time spent in provider visits, and quality of life.
Our latest Survivor Views survey finds that across party lines cancer patients and survivors oppose reducing funding for Medicaid (73%), and fewer than one-in-five support adding a work requirement for Medicaid (19%). The survey also finds overwhelming support for protecting coverage for those with preexisting conditions (81%), and explores questions related to allowing non-ACA plans in the marketplace, which a majority (65%) feel would be confusing.
This factsheet explains what health care tax credits (also known as "enhanced tax credits") are and why Congress needs to extend them before they expire at the end of the year.
Drug therapies are the bedrock of cancer care. Making these therapies affordable, while continuing to encourage innovation of new treatments, is crucial to accomplishing the mission of the American Cancer Society Cancer Action Network (ACS CAN) to end cancer as we know it, for everyone. ACS CAN has long fought for public policies that support both the affordability and availability of medically necessary prescription drugs.
Prescription drug costs are a significant burden on cancer patients and survivors, sometimes even leading patients to miss or delay taking prescribed medications. The latest Survivor Views survey explores the role copay assistance programs can play in reducing this burden, and also addresses patient navigation and digital therapeutics.
A majority of cancer patients and survivors struggle to afford cancer care and over 80% have had to make financial sacrifices to cover their health care expenses. This survey also reveals ways that affordability concerns can negatively impact care and treatment, and explores issues related to prescription drug coverage and pain management options.
Many cancer patients take multiple drugs as part of their treatment – often for many months or years. While drugs are not the only costly part of cancer treatment, finding ways to reduce these costs for patients and payers will significantly reduce the overall cost burden of cancer.
This Survivor Views survey examined access to and affordability of cancer care. Survivors report insurance-related barriers to obtaining prescriptions, and lower-income respondents in particular have difficulty affording them. 24% of respondents have received a surprise medical bill, 60% of which were more than $500.
Growing drug costs in the United States are placing pressure on health plans to implement strategies to balance drug expenditures and utilization. Utilization management (UM) tactics are frequently used across public and private insurance plan types to control prescription drug spending.
As drug costs in the United States rise, health insurance plans are implementing strategies to balance expenditures and utilization. Plans can employ utilization management (UM) tactics to mitigate prescription drug spending.
The American Cancer Society Cancer Action Network (ACS CAN) submitted comments to the Department of Health and Human Services (HHS) on the Interoperability Standards and Prior Authorization for Drugs Proposed Rule.
ACS CAN also developed a one pager on prior authorization and its impact on cancer patients.
The American Cancer Society Cancer Action Network (ACS CAN) submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the Medicare Drug Price Negotiation Initial Price Applicability Year (IPAY) 2028 public engagement process, including results from patient-experience surveys
The American Cancer Society and the American Cancer Society Cancer Action Network provided joint comments to CMS on the the proposed decision memo for changes to the existing National Coverage Decision (NCD) 210.3 related to screening for colorectal cancer (CRC) using non-invasive biomarker tests
ACS CAN joined with 50 other organizations to applaud Representatives Jodey Arrington (R-TX) and Terri Sewell (D-AL) for sponsoring and prioritizing the passage of the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act (H.R. 842).
ACS CAN teamed up with the Leukemia and Lymphoma Society and RIP Medical Debt to conduct a national survey on the impacts of medical debt and high health care costs. Read a summary of the results.
ACS CAN partnered with the Leukemia and Lymphoma Society and RIP Medical Debt to conduct a national survey on the impacts of medical debt and high health care costs. Read the full results.
Short-term limited duration (STLD) insurance plans do not provide the kind of comprehensive insurance coverage cancer patients need. These plans were designed only as temporary coverage and are not subject to the same Affordable Care Act (ACA) requirements as other health insurance products on the market. As a result, an enrollee who was attracted to the plan’s lower premiums may find – if they are diagnosed with a serious illness like cancer – that the plan does not cover all of their necessary cancer treatments. In these cases, the consumer can be left with catastrophic costs.
Many patients with complex diseases like cancer find it difficult to afford their treatments – even when they have health insurance. Current law establishes a limit on what most private insurance plans can require enrollees to pay in out-of-pocket costs. These limits protect patients from extremely high costs and are essential to any health care system that works for cancer patients and survivors.
A majority of cancer patients and survivors struggle to afford cancer care and over 80% have had to make financial sacrifices to cover their health care expenses. This survey also reveals ways that affordability concerns can negatively impact care and treatment, and explores issues related to prescription drug coverage and pain management options.
High deductible health plans (HDHPs) and health savings accounts (HSAs) are becoming more common in employer-sponsored insurance and the individual and small group markets. These types of plans have risks and features must be implemented carefully so they do not harm cancer patients, survivors or those at risk for cancer.
Cancer patients are particularly vulnerable to spikes in their health care costs because many expensive diagnostic tests and treatments are scheduled within a short period of time, so cancer patients spend their deductible and out-of-pocket maximum quickly. These costs can be difficult to manage over the course of a year, and most monthly budgets simply can’t afford these large bills.
Most patients experience spikes in their health care costs around the time of a cancer diagnosis as they pay their deductible and out-of-pocket maximum. For patients on high deductible plans, this spike can mean bills due for several thousands of dollars within one month.
The U.S. spent approximately $183 billion on cancer-related health care in 2015. This represents a signification portion of the total health care spending in the U.S. And it is expected to keep growing. By 2030 cancer-related health care spending is expected to reach nearly $246 billion.
Cancer patients and survivors must balance reducing their health care costs with ensuring they have comprehensive coverage of services, treatments, and care providers.
ACS CAN submitted comments strongly supporting several policy changes that will make it easier to apply for, enroll in, and maintain enrollment in Medicaid and CHIP.
